New PhIII gives Esperion's CEO a chance to push back against a legion of critics — but can he win back investors?
Esperion $ESPR would like to have back its rep for owning a cholesterol drug designed to hit a sweet spot in the market — without any …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
